Uroxatral
Uroxatral
- Uroxatral can be purchased in the Canada with a prescription only, available in extended-release tablets and blister packs.
- Uroxatral is used for the treatment of Benign Prostatic Hyperplasia (BPH). It works by selectively blocking alpha-1 adrenoceptors, relieving urinary symptoms associated with BPH.
- The usual dosage of Uroxatral is 10 mg once daily, taken after the same meal each day.
- The form of administration is an extended-release tablet.
- The effect of the medication begins within 24 hours.
- The duration of action is approximately 24 hours.
- It is advised not to consume alcohol while taking Uroxatral.
- The most common side effect is dizziness.
- Would you like to try Uroxatral without a prescription?
Basic Uroxatral Information
- INN (International Nonproprietary Name)
- Brand names available in Canada
- ATC Code
- Forms & dosages (e.g., tablets, injections, creams)
- Manufacturers in Canada
- Registration status in Canada
- OTC / Rx classification
International Nonproprietary Name (Inn)
The International Nonproprietary Name (INN) for this medication is Alfuzosin. It falls under a specific category that is recognized globally, ensuring that both healthcare professionals and patients can identify this medication easily.
Brand Names Available in Canada
In Canada, Alfuzosin is marketed under the brand name Uroxatral, which comes in the form of extended-release tablets. Another commonly referenced name internationally is Xatral, which is available in Europe in blister packs.
Atc Code
Alfuzosin is classified within the ATC code G04CA01. This code signifies that it belongs to the genito-urinary system, specifically as an alpha-adrenoreceptor antagonist. Such classification aids healthcare professionals in identifying its therapeutic use more effectively.
Dosage Forms
| Product Name | Form | Dosage | Packaging |
|---|---|---|---|
| Uroxatral | Extended-release tab | 10 mg | Blister strips, Rx only |
| Xatral | Prolonged-release tab | 10 mg | Box of 30 blister tablets |
Manufacturers in Canada
The originator of Alfuzosin is Sanofi, a pharmaceutical giant based in the USA. Additionally, generic versions of this medication are produced by companies such as Teva and Sandoz, making it more accessible to patients across Canada.
Registration Status
Alfuzosin has received approval from several regulatory authorities, including the FDA in the United States, EMA in Europe, and Health Canada. It is important to note that this medication is classified as strictly prescription-only (Rx) in Canada, limiting its availability to those with a valid prescription.
Mechanism of Action
Alfuzosin is particularly effective in treating urinary retention issues caused by an enlarged prostate. It works by selectively blocking alpha-1 adrenoceptors, which helps to relax the muscles within the prostate and bladder. This mechanism reduces urinary resistance, making it easier for patients to urinate.
Onset, Metabolism & Elimination
The onset of action for Alfuzosin typically occurs within two days of starting the medication. It is metabolized primarily in the liver and excreted through urine, highlighting its systemic impact following ingestion.
Drug, Food, and Alcohol Interactions
When taking Alfuzosin, caution is advised regarding potential interactions with other substances:
- Drugs: Users should be careful with strong CYP3A4 inhibitors like ketoconazole and other antihypertensive medications.
- Food: To enhance absorption, it is recommended to take Alfuzosin with food.
- Alcohol: Heavy drinking should be avoided to prevent amplified side effects, especially dizziness.
Approved Uses
Alfuzosin is primarily approved for the treatment of benign prostatic hyperplasia (BPH) in males. This condition is characterized by an enlarged prostate, leading to various urinary symptoms that can affect the quality of life.
Off-Label Uses
While Alfuzosin is not specifically approved for females, it may potentially be used off-label for urinary retention issues in certain cases, though this should be approached cautiously and under professional guidance.
Special Populations
Important considerations for different demographics include:
- Pediatric: Alfuzosin is not indicated for children.
- Elderly: Typical dosing is acceptable, but there may be increased sensitivity to hypotension.
- Pregnancy: This medication is contraindicated due to safety concerns and lack of adequate data.
Considerations
Monitoring for adverse effects is crucial in vulnerable populations, ensuring that therapies remain safe and effective. It is always best to consult healthcare professionals when managing medications in special populations.
Dosage & Administration of Uroxatral
Starting on medication can raise numerous questions. What’s the right dosage? How should it be taken? For treating benign prostatic hyperplasia (BPH), the standard dosage of Uroxatral is set at 10 mg in the extended-release form, which is taken once daily alongside food. This simple daily routine can significantly aid patients in managing their symptoms effectively.
When considering dosage adjustments for specific populations:
- For the elderly, no dose adjustment is typically needed unless hypotension is observed.
- In cases of renal impairment, caution is advised, particularly in severe instances, and patients should be closely monitored.
- If liver impairment is a concern, Uroxatral is contraindicated in cases of moderate to severe insufficiency.
Treatment durations may span months or even years, especially for chronic conditions. Therefore, regular follow-ups with a healthcare provider are essential to assess the continued necessity of the medication.
For proper storage, ensure Uroxatral is kept at room temperature (20–25°C) and protected from moisture and heat. Maintain the original packaging during transport to safeguard its integrity. If a dose is missed, it’s important to take it as soon as remembered, but avoid doubling up if the next dose is near.
Safety & Warnings for Uroxatral
Safety is paramount when starting any new medication. Uroxatral has clear contraindications to be aware of:
- Absolute contraindications include moderate to severe liver insufficiency and any hypersensitivity to alfuzosin.
Relative contraindications may involve mild liver impairment, severe renal impairment, or a history of orthostatic hypotension. Observing these can prevent complications and enhance treatment effectiveness.
Side effects may range from mild to severe:
| Common (≥1%) | Moderate/Severe |
|---|---|
| Dizziness | Syncope (fainting) |
| Headache | Severe hypotension |
| Upper respiratory infection | Hypertension reactions |
| GI disturbances (nausea) | IFIS during cataract surgery |
Women who are pregnant should use caution, as there’s a notable risk of syncope. Awareness is crucial in surgical settings due to increased risks involved. Thankfully, Uroxatral does not come with any black box warnings, making it easier for patients and providers to rely on its use in appropriate circumstances.
Patient Experience with Uroxatral
What are real patients saying about their experience with Uroxatral? Reviews from platforms like Drugs.com and Reddit underscore its effectiveness in managing BPH symptoms while also pointing out side effects such as dizziness.
Users commonly share feelings of fatigue and varying degrees of symptom relief, which highlight the medication's differing effects on individuals.
Adherence to the prescribed regimen does not seem to pose major concerns for most users. However, many express a need for ongoing dialogue with their healthcare professionals to optimize their treatment journey.
Alternatives & Comparison of Uroxatral
When it comes to managing benign prostatic hyperplasia (BPH), many patients wonder about options beyond Uroxatral.
Common alternatives in Canada include:
- Hytrin (Terazosin)
- Cardura (Doxazosin)
- Flomax (Tamsulosin)
Here’s a look at how Uroxatral compares to these alternatives:
| Brand Name | Active Ingredient | Effectiveness | Price (CAD) | Availability |
|---|---|---|---|---|
| Uroxatral | Alfuzosin | High | 50-80 | Common |
| Hytrin | Terazosin | Moderate | 40-60 | Common |
| Cardura | Doxazosin | Moderate | 30-55 | Common |
Doctors often prefer Uroxatral due to its specific indications for BPH management.
Market Overview of Uroxatral
Uroxatral can easily be found in major Canadian pharmacies such as Catena and HelpNet.
The average price for a month’s supply typically ranges from $50 to $80.
For convenience, it's available in both blister packs and bottles, ensuring proper dosing.
Demand for Uroxatral has noticeably increased among older demographics. Additionally, seasonal impacts on demand have proven minimal. Throughout COVID-19, demand remained stable.
Research & Trends Surrounding Uroxatral
Recent studies from 2022 to 2025 have shed light on the effectiveness of Uroxatral and have identified potential new applications in urology.
Research is also investigating its use for conditions like bladder outlet obstruction, extending beyond its current approval for BPH.
As the patent on Uroxatral nears expiration in 2024, the market is seeing a rise in generic options. This could mean broader access for patients who need BPH management.